Development of Specific Inhibitors of Alternative Splicing Events Crucial to HIV Replication: A New Anti-HIV/AIDS Strategy

开发对 HIV 复制至关重要的选择性剪接事件的特异性抑制剂：一种新的抗 HIV/艾滋病策略

• 批准号: 246915
• 负责人: Grierson David S
• 金额: $ 29.08万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2011
• 资助国家: 加拿大
• 起止时间: 2011-09-01 至 2014-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=246915&lang=en
• 关键词: Aids; Alternative Splicing Inhibitors; Anti Hiv/Aids Drugs; Dha Analogues; Drug Discovery; Hiv; Screening; Spliceosome

An estimated 33 million people live with HIV/AIDS. Although access to Highly Active Anti-Retroviral Therapy (HAART) has dramatically changed the prognosis of HIV infection, issues of drug compliance, resistance and side effects necessitiates the constant

估计有3 300万人感染艾滋病毒/艾滋病。虽然获得高效抗逆转录病毒治疗（HAART）已经极大地改变了艾滋病毒感染的预后，但药物依从性，耐药性和副作用的问题仍然存在。